Acute Onset of a Life-Threatening Skin Toxicity Due to Osimertinib: Severe Psoriasis Versus Toxic Epidermal Necrolysis

Osimertinib is a third-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor currently used as first-line systemic therapy for advanced EGFR mutant non-small cell lung cancer. Osimertinib is generally very well tolerated with only a 1% risk of grade 3-4 skin toxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Rittberg, Rebekah, Ho, Cheryl, Wang, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138393/
https://www.ncbi.nlm.nih.gov/pubmed/35651371
http://dx.doi.org/10.7759/cureus.24513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138393/
https://www.ncbi.nlm.nih.gov/pubmed/35651371
http://dx.doi.org/10.7759/cureus.24513

Ejemplares similares